A single arm phase II trial of single agent gefitinib (an EGFR inhibitor) in synovial sarcoma (SS) has shown a low response rate of 21% and 6% at four and six months, respectively [17], and the use of the anti-EGFR antibody Cetuximab in advanced soft tissue and bone sarcomas has also only demonstrated rates of 4.8% and 20% at four months [18], and, accordingly, the actual efficacy of EGFR inhibition in sarcoma remains unclear. This evidence concerns the gene EGFR and synovial sarcoma.